Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Tissue Cell ; 88: 102375, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38604038

ABSTRACT

Polycystic Ovary Syndrome (PCOS) is a multifactorial reproductive, endocrine and metabolic disturbance which is very commonly observed in females of reproductive age group. The disease is still incurable however the use of synthetic drugs in combination with lifestyle is recommended. Accordingly, the present study was conducted to investigate the possible beneficial effects of sitagliptin on PCOS induced rats on control diet (CD)/high fat- high fructose diet (HFFD). PCOS was induced by giving testosterone propionate (TP) for 28 days to both the CD/HFFD rats and treated with STG i.p. for last 15 days. At the end of the experiment lipid profile, inflammatory markers, expression of NF-κB-p65, miR-24 and miR-29a, fibrotic and apoptotic proteins from ovary tissue were examined. Moreover, lipid accumulation and fibrosis of ovary tissue was further confirmed using Sudan III and Masson's trichrome stain. STG treated rats exerted a significant decrease in levels of cholesterol, TG, LDL-C, VLDL-C, IL-6 and TNF-α and increased HDL-C level, miR-24 and miR-29a expression. STG treated groups expressed significantly decreased expression of NF-κB-p65, TGF-ß1, p-Smad 2 and p-Smad 3 followed by no significant changes in the expression of BAX, caspase-9, caspase-3 and Bcl-2 in all the PCOS induced groups. Among all the CD/ HFFD fed groups, rats on HFFD showed more devastating effect which suggests that diet plays a major role in genesis of PCOS. In conclusion, current results reflect the potential impact of STG against dyslipidaemia, inflammation and fibrosis in PCOS rats via regulating dyslipidaemia and fibrosis via DPP 4 mediated miR-29a expression.


Subject(s)
Diet, High-Fat , Fructose , MicroRNAs , Polycystic Ovary Syndrome , Signal Transduction , Sitagliptin Phosphate , Transforming Growth Factor beta , Animals , Polycystic Ovary Syndrome/metabolism , Polycystic Ovary Syndrome/chemically induced , Polycystic Ovary Syndrome/pathology , MicroRNAs/metabolism , MicroRNAs/genetics , Female , Fructose/adverse effects , Rats , Sitagliptin Phosphate/pharmacology , Diet, High-Fat/adverse effects , Signal Transduction/drug effects , Transforming Growth Factor beta/metabolism , Rats, Wistar , Dipeptidyl Peptidase 4
3.
Toxicol Mech Methods ; 23(4): 223-34, 2013 May.
Article in English | MEDLINE | ID: mdl-23193997

ABSTRACT

CONTEXT: This study aimed to evaluate the renoprotective action of linalool (LIN) on streptozotocin (STZ)-induced diabetic rats. OBJECTIVE: The pathological changes in diabetic nephropathy (DN) include oxidative stress, renal injury, matrix accumulation and podocyte abnormalities. We investigated the renoprotective actions of LIN, a monoterpene alcohol, present in herbal essential oils in STZ-induced diabetic rats with renal injury. MATERIALS AND METHODS: STZ-diabetic rats were administered LIN (25 mg/kg) for 45 days, after which the activities of key enzymes of glucose metabolism, collagen content, oxidative damage and expression of glucose transporter-1 (GLUT-1), transforming growth factor-ß1 (TGF-ß1), nuclear factor-κBp65 (NF-κB p65) and nephrin were analyzed. RESULTS: Diabetic rats displayed altered glucose metabolism, collagen accumulation and increased TGF-ß1 and NF-κB expression in kidney. LIN treatment restored glucose-metabolizing enzymes, collagen content and GLUT-1 expression and also prevented nephrin loss. LIN also rescued kidney from oxidative stress and inflammation by decreasing the expression of TGF-ß1 and NF-κB. Ultrastructural changes such as basement membrane thickening, reduction in podocyte number and loss of filtration barrier integrity in diabetic rats were mitigated by LIN. DISCUSSION AND CONCLUSION: The results of this study suggest that LIN can attenuate nephropathic changes induced in kidney of diabetic rats. These findings highlight the utility of LIN as a potential drug to treat renal damage in diabetic subjects.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Diabetes Mellitus, Experimental/complications , Diabetic Nephropathies/prevention & control , Extracellular Matrix/drug effects , Kidney/drug effects , Monoterpenes/therapeutic use , Podocytes/drug effects , Acyclic Monoterpenes , Animals , Anti-Inflammatory Agents/administration & dosage , Biomarkers/metabolism , Diabetes Mellitus, Experimental/immunology , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Diabetic Nephropathies/immunology , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Extracellular Matrix/immunology , Extracellular Matrix/metabolism , Kidney/immunology , Kidney/metabolism , Kidney/ultrastructure , Male , Microscopy, Electron, Transmission , Monoterpenes/administration & dosage , Podocytes/pathology , Rats , Rats, Wistar , Streptozocin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...